Amgen

We are honored to be named among the top companies in cardiovascular health by PatientView’s first-ever cardiovascular reputation survey. This is a reflection of what truly matters to patient groups: integrity, transparency, patient-centricity, equitable access, and services offerings. At Amgen, patients are our number one priority, and this recognition strengthens our commitment to keep raising the standard in cardiovascular care. 🔗 Read the full report: https://lnkd.in/gYDPJh7X

Amgen is driving continued research in rare disease. Read about our new data from two studies presented at the American College of Rheumatology Convergence 2024. 🔗 https://amgen.ly/4evKOUF #ACR2024

The path to better cardiovascular health starts with awareness. Amgen’s Lisa Head breaks down the complexities of heart health risk factors, warning signs and the importance of early intervention. As we head into American Heart Association's Scientific Sessions at #AHA24, explore the latest insights to stay informed about heart disease: 🔗 https://lnkd.in/gxvMQYxa

The veteran community at Amgen has made a big impact on our teams, providing leadership and technical skills that contribute to our mission of serving patients worldwide. This Veterans Day, we celebrate their accomplishments, their commitment, and their service. Learn more about our veteran community: https://bit.ly/48Iexsd

In honor of Veterans Day, we proudly recognize all of Amgen’s veteran staff members for their dedicated service. Today, we’re spotlighting Mike Berke, former Green Beret, Director of Engineering, and member of Amgen’s Veteran Employee Network. Learn how Mike’s military experience has strengthened his commitment to our mission of serving patients. 🔗 https://amgen.ly/4hMlxbJ

We’re excited to announce three major leadership promotions in our Operations, Technology, and Rare Disease sectors. S Sam Guhan has been promoted to Senior Vice President, Global Engineering, overseeing Amgen’s infrastructure and Environmental, Health and Safety organization. Sam is also the executive sponsor for Amgen's sustainability plan, serves on the Amgen Foundation Board of Directors, and supports the RIVER (Recognition of Indigenous Peoples, Values & Environmental Resources) employee resource group. Scott Skellenger has been promoted to Senior Vice President and Chief Information Officer, leading our global Technology strategy, digital risk management, and technological modernization. Scott's responsibilities will also include enhancing security measures and ensuring Amgen's technology infrastructure aligns with business objectives. Jasper van Grunsven, VP General Manager of the U.S. General Medicines Business Unit, assumes the role of Senior Vice President, Rare Disease, where he will also continue to lead Amgen’s Global Customer Capabilities and Customer Data & Analytics teams. Congratulations to Sam, Scott, and Jasper. These promotions are key to Amgen's continued success during this critical growth phase in our mission to serve patients.

How can we improve care for people facing serious illnesses? At Amgen, it starts with bringing everyone to the table. By listening to advocacy organizations and patients, and understanding their unique challenges, we can work together to address unmet needs for people facing serious illnesses. Their strength and stories inspire us every day — we couldn’t do our work without them. 🔗 Learn more: https://amgen.ly/3NWP5Wm

Delivering bold solutions for people living with #obesity and related conditions is not just a priority—it’s a mission we’re fiercely dedicated to at Amgen.  This year’s The Obesity Society #ObesityWeek conference brought together researchers, advocates, and other healthcare leaders, sparking dynamic conversations, fresh ideas, and inspiring collaborations to push boundaries and advance patient care. Thank you, ObesityWeek, for creating an environment where we can work toward building a healthier future together. 🔍 Learn more about our approach to addressing the unmet needs of people living with obesity and related conditions at amgen.com/obesity. #OW2024 

Today, Amgen and AstraZeneca announced positive top-line results from their Phase 3 WAYPOINT trial evaluating a treatment for adults affected by chronic rhinosinusitis with nasal polyps (#CRSwNP). 🔗 Press Release: https://amgen.ly/3YEbKeX

What an honor! 🏆 TIME names Amgen’s targeted immunotherapy for small cell lung cancer one of the Best Inventions of 2024. Our innovation provides a new option for treating small cell lung cancer – one of the most aggressive and devastating forms of cancer. #TimeBestInventions